Presentation

Company Profile
Immunicum is a Swedish company which is targeting solid and blood-borne cancers with intratumoral priming and cancer relapse vaccination. The company has products that follow two distinct approaches for achieving the desired therapeutic result. Firstly, the company develops immune primers (P) that aim to activate the patient’s own immune system against cancer. At the same time, the relapse vaccines (V) are targeted to help the immune system control the residual disease following initial treatment and reduce the recurrence of the tumour. By combining these two approaches, the company aims to provide more effective cancer therapy and to minimise the chance of relapse following treatment. The company had two clinical programmes: Ilixadencel (P) and DCP-001 (V).

Recent highlights
In December 2020, Immunicum announced the completion of the business combination with DCPrime, which developed cancer relapse vaccines aimed to reduce tumour recurrence. In January 2021, the company announced that they received FDA Orphan Drug Designation (ODD) for Ilixadencel as a treatment of Soft Tissue Sarcoma (STS). In June, the company announced enrolment of first patient in Phase I ALISON study evaluating cancer relapse vaccine candidate DCP-001 in ovarian cancer. In July, the company announces positive review by data safety monitoring board for Phase Ib Part of ILIAD Study.

Outlook
The company’s focus is to progress Ilixadencel in solid tumours and DCP-001 in blood-borne tumours, while expanding and further developing the preclinical pipeline. The company expects top-line efficacy results from the Phase II DCP-001 study in AML patients.